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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Paclitaxel and rosiglitazone are primarily
metabolized by CYP2C8 and their in vitro
metabolism by human liver microsomes is
correlated. Probe assays that quantify the
in vivo activity of CYP enzymes which are
important in drug metabolism have been
developed for use in clinical pharmacology
research. A probe of CYP2C8 that is easy to
administer and interpret may be valuable
for individualized dosing of paclitaxel.
WHAT THIS STUDY ADDS
• This pilot study demonstrates for the first
time that there is an in vivo correlation
between paclitaxel and rosiglitazone
exposure. The finding, that a single
rosiglitazone plasma concentration after
oral dosing may explain significant variance
in paclitaxel exposure, suggests that
rosiglitazone may satisfy the requirements
of a clinically useful in vivo probe. However,
it is acknowledged that there is a need for
further studies evaluating the use of
rosiglitazone as a CYP2C8 probe and
quantifying the relationship, in order to
guide dosing of narrow therapeutic index
drugs metabolized primarily by CYP2C8,
such as paclitaxel.
AIMS
To evaluate the use of rosiglitazone and the erythromycin breath test
(ERMBT), as probes of CYP2C8 and CYP3A4, respectively, to explain
inter-individual variability in paclitaxel exposure.
METHODS
The concentration of rosiglitazone at 3 h and ERMBT results were
included in a regression model to explain the variability in paclitaxel
exposure in 14 subjects.
RESULTS
Rosiglitazone concentration was significantly correlated with paclitaxel
exposure (P = 0.018) while ERMBT had no predictive value (P = 0.47).
CONCLUSIONS
The correlation between the exposure of rosiglitazone and paclitaxel
likely reflects mutual dependence on the activity of CYP2C8.
Rosiglitazone or similar agents may have value as in vivo probes of
CYP2C8 activity.
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Introduction
Interpatient variability in toxic and therapeutic response to
chemotherapy, partially caused by differences in the activ-
ity of the CYP450 enzyme system, is a substantial problem
in cancer treatment. One emerging approach to character-
ize a drug’s metabolism is through the use of a probe, a
marker agent that shares the drug’s metabolic pathway.
Probe-based tests to measure CYP450 phenotype that
are safe, easy to administer and quickly interpretable
have been developed for some enzymes [1] relevant to
anti-cancer therapy but not all.
Paclitaxel is one of the most effective chemotherapeu-
tic agents used in the treatment of solid tumour malignan-
cies. It is metabolized to inactive metabolites primarily by
CYP2C8 with a contribution from CYP3A4 [2]. A probe
assay that could explain the significant interpatient vari-
ability in paclitaxel exposure might help clinicians select
more appropriate doses for an individual patient to opti-
mize efficacy and limit toxicity.
The erythromycin breath test (ERMBT) has been widely
implemented to measure hepatic CYP3A4 activity [3].
However, there is no such probe for CYP2C8. Interestingly,
the rates of rosiglitazone metabolism and paclitaxel
hydroxylation have been shown to correlate in human liver
microsomes expressing CYP2C8 [4]. In healthy subjects, a
2 mg oral dose of rosiglitazone is safe, >99% bioavailable
and the plasma concentration at 3 h is highly predictive of
AUC(0,•) (r2 = 0.98) (Clarke, S, GlaxoSmithKline, personal
communication), making rosiglitazone an attractive probe
candidate.
Despite the known in vitro correlation, rosiglitazone
has not been previously used as a probe for CYP2C8 to
predict paclitaxel exposure in patients. In this study we
used rosiglitazone and ERMBT as surrogates of CYP2C8
and CYP3A4 activity, respectively, and hypothesized
that the combination of these probes would partially
explain the variability in paclitaxel exposure in cancer
patients.
Methods
This study was conducted at the General Clinical Research
Center (GCRC) and approved by the Institutional Review
Board at UNC Chapel Hill. Eligible patients were >18 years
old with solid tumour malignancies, were scheduled to
receive weekly paclitaxel and provided written informed
consent.
On study day 1, the erythromycin breath test (ERMBT)
was carried out as previously described [5].The percentage
of the dose exhaled as 14C over 1 h (AUC(0,1 h)) was loge
transformed and used as a measure of CYP3A4 activity.
Next, each subject (all of whom fasted for >6 h) was admin-
istered a 2 mg oral dose of rosiglitazone. A blood sample
was collected 3 h after dosing and plasma concentration
analysis was performed as previously described [6] with
an assay lower limit of quantification of 3 ng ml-1 and a
coefficient of variation <15%.
Approximately 6 h after the rosiglitazone dose, each
subject was administered a 1 h infusion of paclitaxel
(75 mg m-2 to 90 mg m-2) as per their standard treatment.
Blood samples (7 ml) were collected prior to infusion and
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 18–24 h after the start of
infusion. Limited sampling, shown to reasonably estimate
paclitaxel exposure [7], was employed for patient conve-
nience.The 18–24 h sample was intended for estimation of
AUC(0,•), which was subsequently deemed unreliable due
to inadequate estimation of the terminal phase elimina-
tion rates. Plasma was separated and stored at -80°C
before undergoing analysis via LC/MS/MS as previously
described with an assay lower limit of quantification of
10 nM and a coefficient of variation < 15%, to measure total
paclitaxel concentration [8].
Paclitaxel pharmacokinetic analysis was performed in
WinNonlin Pro Version 5.2.1 (Pharsight Corp., Mountain
View, CA) using non-compartmental methods. AUC(0,6 h)
was calculated using the linear trapezoidal method and
loge transformed for use in the primary analysis. Prior to
statistical analysis, paclitaxel and rosiglitazone concentra-
tion values were adjusted to correspond to standardized
doses (81.4 and 1.11 mg, respectively) based on the study
mean patient BSA (1.81 m2), to minimize variability due to
differences in doses received and patient size, and were
loge transformed. BSA was selected as the metric for body
composition based on the practice of dosing paclitaxel by
BSA. All later discussion refers to dose-adjusted and loge-
transformed values, except where indicated.
Statistical analysis was conducted in SAS 9.2 (SAS Insti-
tute Inc, Cary, NC) using a multiple linear regression model
with rosiglitazone and ERMBT AUC(0,1 h) the independent
variables and paclitaxel AUC(0,6 h) the dependent vari-
able. Descriptive statistics are reported as mean (SD or
min, max), as appropriate.
Results
Twenty patients with planned or ongoing weekly pacli-
taxel treatment were enrolled. Demographic data for the
14 subjects who had evaluable samples for paclitaxel phar-
macokinetic analysis are displayed in Table 1. The dose-
adjusted mean paclitaxel AUC(0,6 h) was 6787 (2506)
ng ml-1 h, rosiglitazone concentration was 82.3 (26.0)
ng ml-1 and ERMBT AUC(0,1 h) was 2.76% h-1 (1.17). In
the two-variable regression model rosiglitazone was a sta-
tistically significant predictor of paclitaxel AUC(0,6 h)
(P = 0.019). However, ERMBT was not (P = 0.47). After exclu-
sion of ERMBT, rosiglitazone alone explained about 38% of
the variability in paclitaxel AUC(0,6 h) (r2 = 0.38, P = 0.018,
Figure 1). In follow-up exploratory analyses no other
relevant covariates (e.g., age, albumin, cancer type and
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smoking status) significantly contributed to the model
(data not shown).
Discussion
In this pilot study, a 3 h rosiglitazone plasma concentration
after a 2 mg oral dose explained 38% of the variability
in paclitaxel exposure. As expected, higher rosiglitazone
concentrations were associated with increased paclitaxel
exposure. For a variety of reasons, including drug trans-
porters, absorption and compensatory metabolic path-
ways, rosiglitazone may not be the optimal CYP2C8 probe.
Other potential probes, such as pioglitazone which may be
more sensitive to changes in CYP2C8 activity, should also
be considered for further clinical CYP2C8 probe research
[9].
Because this was a small pilot study, supportive analy-
ses of the data were conducted to investigate the robust-
ness of our findings; with results consistent with the
primary analysis. The correlation between paclitaxel
AUC(0,6 h) and rosiglitazone without dose adjustment was
statistically significant (r2 = 0.33, P = 0.029) while adjusting
for mean weight in kg instead of BSA strengthened the
findings modestly (r2 = 0.50, P = 0.004). The correlation
between paclitaxel AUC(0,•) and AUC(0,6 h) was strong (r2
= 0.92) and use of AUC(0,•) instead of AUC(0,6 h) did not
meaningfully change the results (r2 = 0.32, P = 0.034).
Finally, an even better relationship was found (r2 = 0.51,
P = 0.004) when paclitaxel AUC(0,6 h) and rosiglitazone
were rank transformed prior to analysis, suggesting that
the findings did not result from the impact of a particularly
influential value.
The highest rosiglitazone concentration seen was
120 ng ml-1 while the reported Ki of rosiglitazone is
1998 ng ml-1 [10]. Thus, same day administration of rosigli-
tazone and paclitaxel is unlikely to have resulted in com-
petitive enzyme inhibition. In a similar study ERMBT
explained 67% of the variability in clearance of docetaxel
[3], which is metabolized exclusively by CYP3A4. Our
finding that ERMBT was not predictive of paclitaxel clear-
ance was disappointing, but consistent with other evi-
dence that CYP2C8 is the primary enzyme responsible for
paclitaxel metabolism. It is also likely that a portion of our
unexplained variability can be attributed to the role of
drug transporters in the pharmacokinetics of ERMBT and
paclitaxel [11]. It should also be noted that both rosiglita-
zone and paclitaxel are substrates for P-glycoprotein
[12, 13] and this may contribute to the correlation we
observed.
In conclusion, this report supports further study of
rosiglitazone or similar agents as in vivo probes of
CYP2C8 activity in humans. This is the first report of an in
vivo association between rosiglitazone and paclitaxel
exposure and supports the hypothesis that rosiglitazone
may be a reasonable probe for in vivo exposure to
CYP2C8 substrates.
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Table 1
Subject demographic and clinical characteristics






African American 1 (7%)
Other 1 (7%)
Age (years): Mean (min, max) 45.7 (25, 64)
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Relationship between loge rosiglitazone 3 h concentration (x-axis) and
loge paclitaxel AUC(0,6 h) (y-axis) (n = 14). Concentrations of both drugs
were adjusted to a standard (mean) dose per BSA
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